Little is known about the prevalence of secondhand smoke exposure (SHSe) among cancer survivors. We sought to determine the prevalence, trends, and correlates of SHSe among nonsmoking adult cancer survivors in the United States. Interview and serum cotinine data for nonsmoking adults, age 20 years and older, with a history of cancer ( = 686) were obtained from consecutive two-year cross-sectional cycles of the National Health and Nutrition Examination Survey from 1999 to 2012. SHSe was defined as serum cotinine 0.05-10 ng/mL among nonsmokers. We calculated and trended the prevalence of SHSe among nonsmoking cancer survivors. Multivariable logistic regression was used to examine the associations of SHSe with sociodemographic, smoking, and clinical characteristics. Survey weights were applied in estimating prevalence rates, adjusted ORs, and confidence intervals (CI). The weighted aggregate SHSe and self-reported indoor SHSe prevalence rates over the study period were 28.26% (95% CI: 24.97%-31.55%) and 4.53% (95% CI: 3.48%-5.57%), respectively. SHS exposure declined from 39.61% (95% CI: 27.88%-51.34%) in 1999/2000 to 15.68% (95% CI: 9.38%-21.98%) in 2011/2012 ( < 0.001). Age ≥ 60 years was protective against SHSe, while being black, having less than high school education, poverty, and a smoking-related cancer history were associated with higher odds of SHSe. Fortunately, SHSe among nonsmoking cancer survivors in the United States is on the decline, although certain subgroups remain disproportionately burdened. These findings highlight clinical and public health imperatives to target socioeconomically disadvantaged nonsmoking cancer survivors to reduce their SHSe. .

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5671647PMC
http://dx.doi.org/10.1158/1055-9965.EPI-16-0777DOI Listing

Publication Analysis

Top Keywords

cancer survivors
24
survivors united
12
united states
12
shse nonsmoking
12
nonsmoking cancer
12
shse
11
secondhand smoke
8
smoke exposure
8
cancer
8
adult cancer
8

Similar Publications

Adolescent and young adult (AYA) survivors of acute lymphoblastic or myeloid leukemia diagnosed between the ages of 15 and 39 years are at risk for adverse late health effects following cancer treatment and require ongoing survivorship care. This study aims to understand the landscape of transitioning AYAs with leukemia from active treatment to survivorship care. A cross-sectional, anonymous online survey was sent out via listserv/email.

View Article and Find Full Text PDF

Closing the Gap: The Need for Fertility Intervention for Young Adult Cancer Survivors.

J Adolesc Young Adult Oncol

January 2025

The University of Texas Southwestern Medical Center, Moncrief Cancer Institute, Fort Worth, Texas, USA.

The current study identified the fertility-related needs of young adult (YA; ages 19-39) survivors. Participants ( = 94) completed the Adolescent and Young Adult Survivorship Psycho-Oncology Screening Tool-a screening tool developed to assess cancer-related concerns of YAs in survivorship. Approximately one-third of survivors endorsed fertility-related concerns.

View Article and Find Full Text PDF

Objective: Cancer survivors have experienced subjective cognitive impairment (SCI) when they received cancer diagnoses or treatments. Their psychosocial and emotional statuses were also impacted. With the advancement of web technologies, web-based cognitive interventions have been implemented in the management and the alleviation of the SCI, the psychosocial distress, and the emotional distress in cancer survivors.

View Article and Find Full Text PDF

Objectives: To compare the efficacy and safety of three different treatment options (vaginal estriol, vaginal dehydroepiandrosterone (DHEA), and ospemifene) for treating genitourinary syndrome of menopause (GSM) in breast cancer and gynecologic cancer survivors.

Methods: A retrospective comparative analysis was performed among 185 cancer survivors (including breast, endometrial, ovarian, cervical, and vulvar cancer) affected by GSM. Women were divided into three groups according to the prescribed therapy (vaginal estriol, vaginal DHEA, and ospemifene).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!